Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT04520490 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

Brain Activation and Satiety in Children 2

Study acronym: BASIC2
StatusActive, Not Recruiting
PhasePhase 3
Started
View on ClinicalTrials.gov ↗

Record History

See every version on ClinicalTrials.gov ↗

  1. Primary completion date: Feb 21, 2025 to Aug 21, 2025v11
  2. Re-verified, no change to tracked fieldsv10
  3. Primary completion date changed from estimate of Dec 31, 2024 to Feb 21, 2025
    • Study completion date: May 31, 2025 to Feb 12, 2026
    v9
  4. Trial status: Recruiting to Active, Not Recruiting
    • Enrollment target: estimated 64 to confirmed 63
    • Site details revised
    v8
  5. Primary completion date: Nov 30, 2023 to Dec 31, 2024
    • Study completion date: Aug 31, 2024 to May 31, 2025
    v7
Show 5 earlier versionsHide 5 earlier versions
  1. 2 versions Re-verified since Oct 24, 2022, no change to tracked fieldsv5-v6
  2. Primary completion date: Jan 1, 2024 to Nov 30, 2023v4
  3. Trial status: Not Yet Recruiting to Recruiting
    • Start date changed from estimate of Dec 1, 2020 to Jan 28, 2021
    • Site details revised
    v3
  4. Start date: Sep 1, 2020 to Dec 1, 2020
    • Primary completion date: Sep 1, 2023 to Jan 1, 2024
    • Eligibility criteria expanded, about 3 words
    v2
  1. Study First Submitted
  • Stopped: an ongoing trial was terminated, suspended or withdrawn.
  • Notable: the trial’s plan changed such as a big move in its timeline or size, a new primary endpoint, sponsor or phase, or recruiting opened or resumed.
  • Minor: routine progress and housekeeping, such as sites added or enrollment closed.
Childhood obesity and related long-term effects are serious public health problems, but not all children with obesity do well in treatment. This study will test a new combination of family-based behavioral treatment (FBT) with a drug intervention using a glucagon-like peptide-1 receptor agonist (GLP-1RA) exenatide once weekly extended-release (ExQW, Bydureon®) in order to improve obesity intervention outcomes in 10-12-year-old children.
Trial Details
NCT Number NCT04520490
Lead Sponsor Seattle Children's Hospital
Collaborators: University of Washington
Conditions
(from sponsor)		 Childhood Obesity
Related terms Pediatric Obesity
Enrollment 63 participants
Start Date
Primary Completion (estimated)
Study Completion (estimated)
Updated on ClinicalTrials.gov